Frelii Appoints Seasoned Expert as New Board Member to Support Growth & Expand Strategic Positioning
LEHI, Utah--(BUSINESS WIRE)--Dec 20, 2018--Frelii Inc. (OTC Pink: FRLI) (“Frelii” or the “Company”) announced the appointment of Leslie M. Norris to its Board of Directors (the “Board”), effective December 12, 2018.
“Leslie is a respected business leader, strategist and brand expert that will be a powerful catalyst in helping expand Frelii’s position in ever-expanding industries,” said Ian Jenkins, CEO of Frelii. “On behalf of the entire Board, I welcome Leslie, particularly at this time as we emerge into new markets and look to align with forward thinking strategic partners. We feel she is the ideal contributor and advisor, with extensive entrepreneurial and target industry experience, to help shepherd the next phase of Frelii’s growth, vision and innovation.”
Leslie Norris brings nearly 40 years of experience as business strategist and brand expert to the Frelii Board. Norris has worked with Fortune 100, mid-cap, early stage and startups, all in a global capacity. She is currently the Founder and CEO of Springboard5 Marketing, a global strategic PR & Marketing firm that focuses on life science, Biotech and technology companies. She is also Founder and CEO of ARCexperts, a global audit, risk and regulatory compliance firm. In addition, she serves as an independent consultant and advisor to tech and life science companies, providing insight for business planning, executive leadership, operational efficiency, strategic planning and global emergence. Norris has been an angel investor for 25 years and has worked with investment groups in the US and Europe.
As an executive officer, she has headed not only her own companies, but served as interim CXO for a number of companies throughout her career. Most of those engagements were to assist dozens of companies through investment phases, mergers and innovative acquisition strategies; recognizing that in today’s market, unique IP and acquisition strategies are a must for strong investor and shareholder success. Leslie has received numerous awards for her achievements as a professional and entrepreneur. Although she brings a somewhat conservative business nature to each endeavor, she strongly believes in remaining agile and forward thinking, as obsolesce is something that professionals and companies alike must be vigilant to avoid.
“Frelii is the kind of organization that has the potential to shape the Biotech and genetic sequencing industries globally,” said Leslie Norris, Frelii Board member. “The potential for this organization is boundless. We will be emerging into market segments where we can position the company to secure ideal partnerships and revenue streams, through its progressive technology and AI.”
About Frelii Inc.
Frelii Inc. is a medical technology company that uses gene sequencing and artificial intelligence to determine risk and lifestyle modifications. Its technology analyzes the most comprehensive markers (60,000,000 +) on the market to date. Frelii’s technology generates accurate and profoundly valuable insight into DNA. It opens opportunities never before realized in health care, precision medicine, insurance, corporate wellness as well as personal health and risk identification. For more information, please visit www.frelii.com.
Follow Frelii online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/ Frelii Twitter Feed @livefrelii Frelii Instagram Page @livefrelii Frelii LinkedIn Page linkedin.com/company/frelii/
Safe Harbor Statement:
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181220005249/en/
CONTACT: Tim Rush
KEYWORD: UTAH UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: TECHNOLOGY HEALTH OTHER SCIENCE OTHER TECHNOLOGY RESEARCH SOFTWARE GENERAL HEALTH GENETICS SCIENCE DATA MANAGEMENT
SOURCE: Frelii Inc.
Copyright Business Wire 2018.
PUB: 12/20/2018 05:09 AM/DISC: 12/20/2018 06:01 AM